Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06302413
Other study ID # 1805574553; Aims 9-10
Secondary ID 1R01AA029396-01
Status Recruiting
Phase N/A
First received
Last updated
Start date February 15, 2024
Est. completion date July 31, 2027

Study information

Verified date March 2024
Source Indiana University
Contact Sarah Turo, BA
Phone 317-963-7220
Email sturo@iu.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical trial is to use a novel virtual reality intervention to test for efficacy in reducing alcohol use and increasing abstinence, with concomitant increases in future self-identification, future time perspective, and delay-of-reward, in early recovering alcohol use disorder (AUD) persons. The main question[s] this trial aims to answer are: Will the Virtual Reality (VR) intervention decrease the number of stimulant use days? Will the VR intervention produce longer abstinence periods during follow-up visits? Will the VR intervention increase alcohol abstinence rates? Will the VR intervention increase future self-identification? Will the VR intervention increase self-reported future time perspective? Will the VR intervention increase preference for delayed rewards in a laboratory delay discounting task on the study day? Will the VR intervention produce gains in the behavioral effects of future self-identification, future time perspective, and delayed rewards at the 30-day and 6-month follow-ups? Researchers will compare the experimental and control groups to see if there are differences in the results for the questions outlined above.


Recruitment information / eligibility

Status Recruiting
Enrollment 500
Est. completion date July 31, 2027
Est. primary completion date July 31, 2027
Accepts healthy volunteers No
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: - Abstinence between =14 days and =1 year - Verbal endorsement of commitment to recovery - Outpatient - Psychotropic drugs for SUD-comorbidity - Drug/alcohol abstinence = 24 hours at the time of the study day visit - English comprehension Exclusion Criteria: - Unstable medical disorders - Habitual drug use - Mu-opioid drugs - Smell/taste disorders - Unstable psychiatric conditions - Extravagant/elaborate face tattoos

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Virtual Reality
They will receive a Virtual Reality Park experience, which is an empty park with no avatars. They will then have a Virtual Reality Avatar experience, where they will see an avatar resembling themselves in a park setting.
Virtual Reality
They will receive a Virtual Reality Park experience, which is an empty park with no avatars.

Locations

Country Name City State
United States Indiana University School of Medicine - Goodman Hal Indianapolis Indiana

Sponsors (2)

Lead Sponsor Collaborator
Indiana University National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Reduced Use of Drug Using Days The Virtual Reality Avatar experience will reduce drug using days. Day 2-Study Day Visit; 30-day Follow-up Visit; 6-month Follow-up Visit
Primary Increased Length of Abstinence The Virtual Reality Avatar experience will increase the length of abstinence periods. Day 2-Study Day Visit; 30-day Follow-up Visit; 6-month Follow-up Visit.
Primary Increased (overall) Abstinence The Virtual Reality Avatar experience will increase abstinence. Day 2-Study Day Visit; 30-day Follow-up Visit; 6-month Follow-up Visit.
Primary Future Self-identification with Future Self Continuity Questionnaire The Virtual Reality Avatar experience will increase future self-identification. Day 2-Study Day Visit; 30-day Follow-up Visit; 6-month Follow-up Visit
Primary Future Time Perspective with the Delayed Discounting Behavioral Task and Future Self Continuity Questionnaire The Virtual Reality Avatar experience will increase future time perspective. Day 2-Study Day Visit; 30-day Follow-up Visit; 6-month Follow-up Visit.
Primary Delayed Reward Preference with the Delayed Discounting Behavioral Task The Virtual Reality Avatar experience will increase preference for delayed rewards. Day 2-Study Day Visit; 30-day Follow-up Visit; 6-month Follow-up Visit.
See also
  Status Clinical Trial Phase
Recruiting NCT04788004 - Long-term Recovery: Longitudinal Study of Neuro-behavioral Markers of Recovery and Precipitants of Relapse
Recruiting NCT05684094 - Mechanisms of Risky Alcohol Use in Young Adults: Linking Sleep to Reward- and Stress-Related Brain Function N/A
Completed NCT03406039 - Testing the Efficacy of an Online Integrated Treatment for Comorbid Alcohol Misuse and Emotional Problems N/A
Completed NCT03573167 - Mobile Phone-Based Motivational Interviewing in Kenya N/A
Completed NCT04817410 - ED Initiated Oral Naltrexone for AUD Phase 1
Active, not recruiting NCT04267692 - Harm Reduction Talking Circles for American Indians and Alaska Natives With Alcohol Use Disorders N/A
Completed NCT03872128 - The Role of Neuroactive Steroids in Stress, Alcohol Craving and Alcohol Use in Alcohol Use Disorders Phase 1
Recruiting NCT06030154 - Amplification of Positivity for Alcohol Use N/A
Active, not recruiting NCT05419128 - Family-focused vs. Drinker-focused Smartphone Interventions to Reduce Drinking-related Consequences of COVID-19 N/A
Completed NCT04564807 - Testing an Online Insomnia Intervention N/A
Completed NCT04284813 - Families With Substance Use and Psychosis: A Pilot Study N/A
Completed NCT04203966 - Mental Health and Well-being of People Who Seek Help From Their Member of Parliament
Recruiting NCT05861843 - Craving Assessment in Patients With Alcohol Use Disorder Using Virtual Reality Exposure
Terminated NCT04404712 - FAAH Availability in Psychiatric Disorders: A PET Study Early Phase 1
Enrolling by invitation NCT04128761 - Decreasing the Temporal Window in Individuals With Alcohol Use Disorder N/A
Not yet recruiting NCT06163651 - Evaluating a One-Year Version of the Parent-Child Assistance Program N/A
Not yet recruiting NCT06337721 - Preventing Alcohol Use Disorders and Alcohol-Related Harms in Pacific Islander Young Adults N/A
Enrolling by invitation NCT02544581 - Preliminary Analysis of the Soberlink Alcohol Breath Analyzer System's (SABA) Clinical Utility During Aftercare N/A
Completed NCT02511886 - A Dose-Escalation Study to Determine the Maximum Tolerated Dose of Arbaclofen Placarbil in Subjects With Alcohol Use Disorder Phase 2
Active, not recruiting NCT02185131 - Double-blind Pilot Trial of Mirtazapine for the Treatment of Co-occurring AD/MDD. Phase 2